Isabella Bank (ISBA) Q1 2025 earnings summary

Executive summary

• Net income for Q1 2025 was $3,949 ($0.53 per diluted share), up from $3,131 ($0.42) in Q1 2024; adjusted/core net income was $4,254 ($0.57 per share) versus $3,076 ($0.41) last year, driven by higher loan interest income and lower provision for credit losses, partially offset by higher noninterest expenses.

• Net interest income rose to $14,525, with net interest margin (NIM) at 3.06% (up from 2.79%); loan yields expanded to 5.71% from 5.38% year-over-year, while cost of interest-bearing liabilities decreased to 2.26%.

• Return on average assets improved to 0.77% from 0.61% year-over-year.

• Commercial & industrial loans grew 7% annualized; non-maturity deposits grew 14% annualized.

• Noninterest income increased slightly to $3,528, with higher wealth management fees and BOLI earnings; noninterest expenses rose 4.9% to $13.3 million, mainly due to compensation and legal fees.

Financial highlights

• Total assets grew to $2,102,587, mainly from increases in cash, securities, and BOLI assets, offset by a reduction in advances to mortgage brokers.

• Loans outstanding at March 31, 2025, were $1,367,724, down $55,847 from year-end due to lower advances to mortgage brokers; core loans grew $4,218, led by commercial real estate and industrial portfolios.

• Total deposits increased $50,849 to $1,797,909, driven by growth in interest-bearing and savings accounts.

• Allowance for credit losses (ACL) was $12,735 (0.93% of gross loans), down from $12,895 at year-end, reflecting improved historical loss experience and recoveries.

• Nonaccrual loans decreased to $173 from $282; past due loans remained stable at 0.41% of total loans.

Outlook and guidance

• Management expects continued NIM expansion as more loans reprice and cost of liabilities stabilizes.

• The commercial loan pipeline remains robust, with anticipated closings in Q2 2025.

• Full impact of BOLI restructuring expected by Q3 2025, with further fee-based income enhancements planned.

• No material changes to risk factors or market risk exposure are expected in the near term.